Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancer

• DOI: 10.3389/fmed.2023.1338566
• Publication Date: 2024-01-16T04:30:11Z
• Authors: Neil Carleton; Julia Foldi
• Keywords: Abemaciclib; Medicine (General); 03 medical and health sciences; R5-920; 0302 clinical medicine; hyponatremia; early-stage breast cancer; ER+ breast cancer; SIADH; Medicine

The CDK4/6 inhibitor, abemaciclib, is now the standard of care adjuvant therapy for patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) tumors at high risk recurrence. Real-world usage uncovers emerging side effects that may have been previously unreported in clinical trials. Here, we present course a patient who developed syndrome inappropriate antidiuretic hormone (SIADH) without underlying kidney injury due to abemaciclib use.